This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the
monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a
dose-escalation stage and an expansion stage.
Multiple Myeloma, Myeloma
FT576 (Allogenic CAR NK cells with BCMA expression)
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.